HMB-45
WikiDoc Resources for HMB-45 |
Articles |
---|
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on HMB-45 at Clinical Trials.gov Clinical Trials on HMB-45 at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on HMB-45
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Directions to Hospitals Treating HMB-45 Risk calculators and risk factors for HMB-45
|
Healthcare Provider Resources |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
HMB-45 is a monoclonal antibody that reacts against an antigen present in melanocytic tumors such as melanomas. It is used in anatomic pathology as a marker for such tumors.
HMB-45 was discovered by Drs. Allen M. Gown and Arthur M. Vogel in 1986.[1] The antibody was generated to an extract of melanoma. It reacted positively against melanocytic tumors but not other tumors, thus demonstrating specificity and sensitivity. Moreover, the antibody reacts positively against junctional nevus cells but not intradermal nevi, and against fetal melanocytes but not normal adult melanocytes. HMB stands for Human Melanoma Black.
References
External links
- Melanoma antibody (ab787) datasheet - abcam.com.